CTIS2023-503208-94-00RecruitingPhase 1
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer - CAAA617A12402
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- ovartis Pharma AG
- Enrollment
- 704
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- Male
Inclusion Criteria
- •Must have received at least one dose of AAA617 within an interventional, phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.
Exclusion Criteria
- •Inability to complete the needed investigational examinations due to any reason.
Investigators
Similar Trials
Active, not recruiting
Phase 4
To assess safety and effectiveness of Rivaroxaban(Xarelto)in managing coronary and or symptomatic peripheral artery disease in Indian PatientsCTRI/2022/01/039597Bayer Zydus Pharma Pvt Ltd
Active, not recruiting
Not Applicable
Post-authorization safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human erythropoietin alfa i.v. - NDEUCTR2007-005728-34-ITHEXAL BIOTECH1,500
Not yet recruiting
Phase 4
A study to check safety and efficacy of Pregabalin Prolonged Release and Etoricoxib Tablet in patients with Chronic Low Back Pain Associated with Neuropathic ComponentCTRI/2022/05/042521Sun Pharma Laboratory Limited SP
Active, not recruiting
Phase 1
Post-authorization Phase IV effectiveness and safety multicentric study of COVID-19 vaccines – CoVigiEUCTR2021-000566-14-CZMasarykova univerzita565
Completed
Phase 4
Phase IV, Open-label Study to Assess the Safety of H5N1 Pre-pandemic Vaccine (BK-KIB-01)JPRN-jRCT1090220019ational Hospital Organization Mie National Hospital6,000